-62%

est. 2Y upside i

HealthcareSeries A

Xaira is reinventing drug R&D using artificial intelligence to rapidly prototype and test disease treatments.

Rank

#1557

Sector

Biotech / AI Drug Discovery

Est. Liquidity

~7Y

Data Quality

Data: Low

Xaira is a pure moonshot: $1B pre-revenue on the world's best AI biology team.

Last updated: March 21, 2026

Bull (20%)+400%

AI-designed antibodies succeed in clinic. $10B+ pipeline value. IPO at major premium.

Base (30%)+60%

Platform shows promise; partnership deals at $500M-$1B. Modest returns on $1B raised.

Bear (50%)-70%

AI-to-drug translation fails clinically. Long timelines exhaust capital. Restructure.

Est. time to liquidity~7.0 years

Preference Stack Risk

moderate

$1B raised; but if val is $5B+, intensity is low. Unknown val.

Dilution Risk

high

Pre-revenue; many rounds before commercialization.

Secondary Liquidity

none

Launched 2024; no secondary.

Other — 1 role

View all 1 open roles at Xaira →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Xaira's data — designed to show you've done your homework.

  • 1

    “IND filing timeline?”

  • 2

    “Clinical validation strategy?”

  • 3

    “Platform vs pipeline revenue model?”

Community

Valuation Sentiment

Our model estimates -62% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.